
**UPDATES ON A LITIGATION PROCEEDING IN THE PEOPLE'S REPUBLIC OF CHINA
- CLAIM BY HEALTH KIND INTERNATIONAL (SHANGHAI) LIMITED**

1. QUE Lippo Healthcare Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) refers to the announcements of the Company between 22 February 2017 and 30 July 2021 in relation to the on-going litigation with Weixin Hospital Investment Management (Shanghai) Co. Ltd (卫心医院投资管理(上海)有限公司) (“**Weixin**”),¹ in particular the following announcements:
 - (a) the announcement dated 26 February 2021 in relation to the unjust enrichment claim commenced by Health Kind International (Shanghai) Limited (“**Healthkind Shanghai**”, a subsidiary of the Company) on 10 February 2021 before the People’s Court of Pudong District against Weixin and Wuxi New District Phoenix Hospital Co., Ltd. (“**Wuxi Co**”, a subsidiary of Weixin) for the sum of RMB 50 million, contending that Weixin was unjustly enriched in the sum of RMB 50 million, being the increase in equity value of Wuxi New District Phoenix Hospital (the “**Wuxi Hospital**”) from 2010 to 2018 pursuant to manpower, resources and funds invested by Healthkind Shanghai (the “**Unjust Enrichment Claim**”); and
 - (b) the announcement dated 30 July 2021 in relation to the hearing for the Unjust Enrichment Claim scheduled on 23 September 2021.
2. Subsequent to the hearing, the Company was informed by its PRC Counsel on 21 October 2021 that the People’s Court of Pudong District has issued a judgment dismissing Healthkind Shanghai’s claims on 15 October 2021. In doing so, the People’s Court of Pudong District held, amongst others, that there was insufficient evidence to prove the loss caused to Healthkind Shanghai, or whether the loss was caused by Weixin.
3. The Company has been advised by its PRC Counsel that, given the positive progress the Company has made on various legal proceedings against David Lin Kao Kun and his related entities, as the Company has previously announced via SGXNet, it will not be necessary to appeal against the decision of the People’s Court of Pudong District.
4. As and when there are material developments, the Company will provide further updates on the status of the above matters through SGXNet in accordance with the requirements under the applicable Catalist Rules.

By Order of the Board
QUE Lippo Healthcare Limited

Mr. Yet Kum Meng
Chief Executive Officer and Executive Director
24 October 2021

¹ Please refer to the Company’s announcements dated 22 February 2017, 20 December 2017, 6 August 2018, 23 August 2018, 30 November 2018, 5 December 2018, 27 December 2018, 29 January 2019, 28 February 2019, 28 March 2019, 29 April 2019, 31 May 2019, 28 June 2019, 30 July 2019, 30 August 2019, 30 September 2019, 14 October 2019, 30 October 2019, 25 November 2019, 29 November 2019, 12 December 2019 and 30 December 2019, 31 January 2020, 28 February 2020, 30 March 2020, 29 May 2020, 30 June 2020, 30 July 2020, 31 August 2020; 29 September 2020, 29 October 2020, 30 November 2020, 31 December 2020, 29 January 2021, 26 February 2021, 22 March 2021, 31 March 2021, 30 April 2021, 31 May 2021, 29 June 2021 and 30 July 2021.

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Ms. Foo Jien Jieng, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.